|
1
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
|
2
|
Pyaskovskaya ON, Dasyukevich OI, Kolesnik
DL, Garmanchouk LV, Todor IN and Solyanik GI: Changes in VEGF level
and tumor growth characteristics during Lewis lung carcinoma
progression towards cis-DDP resistance. Exp Oncol. 29:197–202.
2007.PubMed/NCBI
|
|
3
|
Tanaka N, Miyajima A, Kosaka T, Miyazaki
Y, Shirotake S, Shirakawa H, Kikuchi E and Oya M: Acquired platinum
resistance enhances tumour angiogenesis through angiotensin II type
1 receptor in bladder cancer. Br J Cancer. 105:1331–1337. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fleming I, Kohlstedt K and Busse R: The
tissue renin-angiotensin system and intracellular signalling. Curr
Opin Nephrol Hypertens. 15:8–13. 2006. View Article : Google Scholar
|
|
5
|
Arici M and Erdem Y: Dual blockade of the
renin-angiotensin system for cardiorenal protection: An update. Am
J Kidney Dis. 53:332–345. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoshiji H, Noguchi R, Toyohara M, Ikenaka
Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, et al:
Combination of vitamin K2 and angiotensin-converting enzyme
inhibitor ameliorates cumulative recurrence of hepatocellular
carcinoma. J Hepatol. 51:315–321. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakai Y, Isayama H, Ijichi H, Sasaki T,
Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y,
et al: Inhibition of renin-angiotensin system affects prognosis of
advanced pancreatic cancer receiving gemcitabine. Br J Cancer.
103:1644–1648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wilop S, von Hobe S, Crysandt M, Esser A,
Osieka R and Jost E: Impact of angiotensin I converting enzyme
inhibitors and angiotensin II type 1 receptor blockers on survival
in patients with advanced non-small-cell lung cancer undergoing
first-line platinum-based chemotherapy. J Cancer Res Clin Oncol.
135:1429–1435. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tatokoro M, Fujii Y, Kawakami S, Saito K,
Koga F, Matsuoka Y, Iimura Y, Masuda H and Kihara K: Phase-II trial
of combination treatment of interferon-α, cimetidine,
cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor
(I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci.
102:137–143. 2011. View Article : Google Scholar
|
|
10
|
Imai N, Hashimoto T, Kihara M, Yoshida S,
Kawana I, Yazawa T, Kitamura H and Umemura S: Roles for host and
tumor angiotensin II type 1 receptor in tumor growth and
tumor-associated angiogenesis. Lab Invest. 87:189–198. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Feng Y, Wan H, Liu J, Zhang R, Ma Q, Han
B, Xiang Y, Che J, Cao H, Fei X, et al: The angiotensin-converting
enzyme 2 in tumor growth and tumor-associated angiogenesis in
non-small cell lung cancer. Oncol Rep. 23:941–948. 2010.PubMed/NCBI
|
|
12
|
Feng Y, Ni L, Wan H, Fan L, Fei X, Ma Q,
Gao B, Xiang Y, Che J and Li Q: Overexpression of ACE2 produces
antitumor effects via inhibition of angiogenesis and tumor cell
invasion in vivo and in vitro. Oncol Rep. 26:1157–1164.
2011.PubMed/NCBI
|
|
13
|
Arnaoutova I, George J, Kleinman HK and
Benton G: The endothelial cell tube formation assay on basement
membrane turns 20: State of the science and the art. Angiogenesis.
12:267–274. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moyes AJ, Maldonado-Pérez D, Gray GA and
Denison FC: Enhanced angiogenic capacity of human umbilical vein
endothelial cells from women with preeclampsia. Reprod Sci.
18:374–382. 2011. View Article : Google Scholar
|
|
15
|
Ino K, Shibata K, Kajiyama H, Nawa A,
Nomura S and Kikkawa F: Manipulating the angiotensin system - new
approaches to the treatment of solid tumours. Expert Opin Biol
Ther. 6:243–255. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ender SA, Dallmer A, Lässig F, Lendeckel U
and Wolke C: Expression and function of the
ACE2/angiotensin(1–7)/Mas axis in osteosarcoma cell lines U-2 OS
and MNNG-HOS. Mol Med Rep. 10:804–810. 2014.PubMed/NCBI
|
|
17
|
Fan L, Feng Y, Wan HY, Ni L, Qian YR, Guo
Y, Xiang Y and Li QY: Hypoxia induces dysregulation of local
renin-angiotensin system in mouse Lewis lung carcinoma cells. Genet
Mol Res. 13:10562–10573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Yang ZL, Ren X, Zou Q, Yuan Y, Liang
L, Chen M and Chen S: ACE2 and FZD1 are prognosis markers in
squamous cell/adenosquamous carcinoma and adenocarcinoma of
gallbladder. J Mol Histol. 45:47–57. 2014. View Article : Google Scholar
|
|
19
|
Ye G, Qin Y, Lu X, Xu X, Xu S, Wu C, Wang
X, Wang S and Pan D: The association of renin-angiotensin system
genes with the progression of hepatocellular carcinoma. Biochem
Biophys Res Commun. 459:18–23. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y,
Li Q, Xiang Y and Gao B: Angiotensin-(1–7) inhibits the migration
and invasion of A549 human lung adenocarcinoma cells through
inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol
Rep. 27:783–790. 2012.
|
|
21
|
Liu Y, Li B, Wang X, Li G, Shang R, Yang
J, Wang J, Zhang M, Chen Y, Zhang Y, et al: Angiotensin-(1–7)
suppresses hepatocellular carcinoma growth and angiogenesis via
complex interactions of angiotensin II type 1 receptor, angiotensin
II type 2 receptor and Mas receptor. Mol Med. 21:626–636. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zong H, Yin B, Zhou H, Cai D, Ma B and
Xiang Y: Loss of angiotensin-converting enzyme 2 promotes growth of
gallbladder cancer. Tumour Biol. 36:5171–5177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Soto-Pantoja DR, Menon J, Gallagher PE and
Tallant EA: Angiotensin-(1–7) inhibits tumor angiogenesis in human
lung cancer xenografts with a reduction in vascular endothelial
growth factor. Mol Cancer Ther. 8:1676–1683. 2009. View Article : Google Scholar : PubMed/NCBI
|
